Gómez, Ana María
Henao Carrillo, Diana Cristina
Ré, Matías Alberto
Faradji, Raquel N.
Flores Caloca, Oscar
de la Garza Hernández, Natalia Eloísa
Antillón Ferreira, Carlos
Garnica-Cuéllar, Juan C.
Krakauer, Marcio
Galindo, Rodolfo J.
Article History
Received: 23 February 2024
Accepted: 27 May 2024
First Online: 12 June 2024
Declarations
:
: Not required.
: Not applicable.
: Rodolfo J. Galindo is partially supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under Award Numbers P30DK111024, K23DK123384 and R03DK138255-01. RJG received research support to Emory University for investigator-initiated studies from Novo Nordisk, Dexcom and Eli Lilly and consulting/advisory/honoraria fees from AstraZeneca, Abbott, Dexcom, Sanofi, Eli Lilly, Novo Nordisk, Bayer, Boehringer. Marcio Krakauer has received grants from and participated in Advisory Boards for Abbott, AstraZeneca, Biomm, Boehringer, Lilly, Medtronic, Merck, MSD, Novo Nordisk, P&G Health, Roche, and Sanofi. Raquel N. Faradji has served as an Advisory Board Member for Abbott. Juan C. Garnica Cuellar has been a speaker for Abbott, Sanofi, Novo Nordisk, Boehringer and AstraZeneca. Ana María Gómez has been a speaker for Abbott, Medtronic, Sanofi, Novo Nordisk, Eli Lilly and AstraZeneca. Diana Cristina Henao Carrillo has received economic compensations as a speaker for Novo Nordisk, Sanofi and Abbott. Natalia de la Garza has been a speaker for Medtronic, Sanofi, BI, Eli Lilly and Abbott. Matías Ré has been speaker for Abbott, AstraZeneca, Boehringer, Medtronic, Novo Nordisk, Roche and Sanofi. Carlos Antillón Ferreira has been a speaker for Medtronic, Abbott, Sanofi, Novo Nordisk, Merck-Serono, Pfizer, Eli-Lilly, Roche, Asofarma, Sandoz.